Anti-SLAMF7 monoclonal antibody
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Anti-SLAMF7 monoclonal antibody, covering 2019-01-28 to 2019-01-28. Get the full timeline:
Most recent: Clinical Trial Update: 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma [Phase 2]